Pluri Inc. director not re-elected, Nasdaq compliance cure period granted

Pluri Inc. (NASDAQ:PLUR) announced that director Doron Birger was not re-elected at its annual shareholder meeting, resulting in his immediate departure as an independent director and chairman of the audit committee. This non-re-election caused Pluri's audit committee to fall out of compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three independent directors. Nasdaq has granted the company a cure period until June 30, 2026, to regain compliance, with Pluri stating its intention to appoint an additional independent director. Separately, shareholders also ratified Kesselman & Kesselman as the independent auditor, approved the 2016 Equity Compensation Plan, and authorized the exercise of warrants for director Alexandre Weinstein under Nasdaq Listing Rule 5635(d).

Analysis

Pluri Inc. is facing a significant governance event following the failure of director Doron Birger to secure re-election at its annual shareholder meeting. This development is notable as Birger was an independent director, chairman of the audit committee, and the sole member of the investment committee. His departure has caused the company to fall out of compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires a minimum of three independent directors on the audit committee. While Nasdaq has issued a formal non-compliance notice, a negative signal, it has also granted a substantial cure period extending to June 30, 2026, at the latest, during which Pluri intends to appoint a replacement. In contrast to this governance disruption, shareholders approved other key proposals, including the ratification of Kesselman & Kesselman (a PwC firm) as auditor and the authorization for an entity owned by director Alexandre Weinstein to exercise warrants. This mixed outcome suggests shareholders are discerning, potentially targeting specific board members while supporting the company's broader operational and financing activities.

Key Decisions for Investors

• Investors should closely monitor for the timely appointment of a new independent director to the audit committee, as failure to regain compliance within Nasdaq's cure period would be a significant negative catalyst.
• The non-re-election of a key committee chairman warrants scrutiny into Pluri's board dynamics and potential shareholder dissatisfaction, representing a key governance risk.
• Consider the approval of an insider-related warrant exercise alongside the ousting of a director as a complex signal, suggesting shareholder support for financing and certain leadership but not for the entire board's composition.